These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 33249200)

  • 21. Long-term complications in patients implanted with subcutaneous implantable cardioverter-defibrillators: Real-world data from the extended ELISIR experience.
    Gasperetti A; Schiavone M; Ziacchi M; Vogler J; Breitenstein A; Laredo M; Palmisano P; Ricciardi D; Mitacchione G; Compagnucci P; Bisignani A; Angeletti A; Casella M; Picarelli F; Fink T; Kaiser L; Hakmi S; Calò L; Pignalberi C; Santini L; Lavalle C; Pisanò E; Olivotto I; Tondo C; Curnis A; Dello Russo A; Badenco N; Steffel J; Love CJ; Tilz R; Forleo G; Biffi M
    Heart Rhythm; 2021 Dec; 18(12):2050-2058. PubMed ID: 34271173
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Primary prevention implantable cardioverter-defibrillators in hypertrophic cardiomyopathy-Are there predictors of appropriate therapy?
    Weissler-Snir A; Dorian P; Rakowski H; Care M; Spears D
    Heart Rhythm; 2021 Jan; 18(1):63-70. PubMed ID: 32800967
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incidence and predictors of implantable cardioverter-defibrillator therapy and its complications in idiopathic ventricular fibrillation patients.
    Blom LJ; Visser M; Christiaans I; Scholten MF; Bootsma M; van den Berg MP; Yap SC; van der Heijden JF; Doevendans PA; Loh P; Postema PG; Barge-Schaapsveld DQ; Hofman N; Volders PGA; Wilde AA; Hassink RJ
    Europace; 2019 Oct; 21(10):1519-1526. PubMed ID: 31114860
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of the 6-min walk distance to identify variations in treatment benefits from implantable cardioverter-defibrillator and amiodarone: results from the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial).
    Fishbein DP; Hellkamp AS; Mark DB; Walsh MN; Poole JE; Anderson J; Johnson G; Lee KL; Bardy GH;
    J Am Coll Cardiol; 2014 Jun; 63(23):2560-2568. PubMed ID: 24727258
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term follow-up of arrhythmogenic right ventricular cardiomyopathy patients with an implantable cardioverter-defibrillator for prevention of sudden cardiac death.
    Yin K; Ding L; Li Y; Hua W
    Clin Cardiol; 2017 Apr; 40(4):216-221. PubMed ID: 28139837
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Subcutaneous implantable cardioverter-defibrillator Post-Approval Study: Clinical characteristics and perioperative results.
    Gold MR; Aasbo JD; El-Chami MF; Niebauer M; Herre J; Prutkin JM; Knight BP; Kutalek S; Hsu K; Weiss R; Bass E; Husby M; Stivland TM; Burke MC
    Heart Rhythm; 2017 Oct; 14(10):1456-1463. PubMed ID: 28502872
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapy optimization in patients with heart failure: the role of the wearable cardioverter-defibrillator in a real-world setting.
    Röger S; Rosenkaimer SL; Hohneck A; Lang S; El-Battrawy I; Rudic B; Tülümen E; Stach K; Kuschyk J; Akin I; Borggrefe M
    BMC Cardiovasc Disord; 2018 Mar; 18(1):52. PubMed ID: 29544442
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes After Implantable Cardioverter-Defibrillator Generator Replacement for Primary Prevention of Sudden Cardiac Death.
    Madhavan M; Waks JW; Friedman PA; Kramer DB; Buxton AE; Noseworthy PA; Mehta RA; Hodge DO; Higgins AY; Webster TL; Witt CM; Cha YM; Gersh BJ
    Circ Arrhythm Electrophysiol; 2016 Mar; 9(3):e003283. PubMed ID: 26921377
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Arrhythmic burden among asymptomatic patients with ischemic cardiomyopathy and an implantable cardioverter-defibrillator.
    Sabbag A; Glikson M; Suleiman M; Boulos M; Goldenberg I; Beinart R; Nof E
    Heart Rhythm; 2019 Jun; 16(6):813-819. PubMed ID: 31153454
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Application of a mortality risk score in a general population of patients with an implantable cardioverter defibrillator (ICD).
    Schaer BA; Kühne MS; Blatter D; Osswald S; Sticherling C
    Heart; 2014 Mar; 100(6):487-91. PubMed ID: 24415667
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Competing risk analysis of cause-specific mortality in patients with an implantable cardioverter-defibrillator: The EVADEF cohort study.
    Marijon E; Trinquart L; Otmani A; Waintraub X; Kacet S; Clémenty J; Chatellier G; Le Heuzey JY;
    Am Heart J; 2009 Feb; 157(2):391-397.e1. PubMed ID: 19185651
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Applicability of a risk score for prediction of the long-term (8-year) benefit of the implantable cardioverter-defibrillator.
    Barsheshet A; Moss AJ; Huang DT; McNitt S; Zareba W; Goldenberg I
    J Am Coll Cardiol; 2012 Jun; 59(23):2075-9. PubMed ID: 22651863
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relation between total shock energy and mortality in patients with implantable cardioverter-defibrillator.
    Tenma T; Yokoshiki H; Mitsuyama H; Watanabe M; Mizukami K; Kamada R; Takahashi M; Sasaki R; Maeno M; Okamoto K; Chiba Y; Anzai T
    Int J Cardiol; 2018 May; 259():94-99. PubMed ID: 29486995
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictors for early mortality and arrhythmic events in patients with cardiac resynchronization therapy with defibrillator: A two center cohort study.
    Gunten SV; Theuns DA; Kühne M; Reichlin T; Sticherling C; Schaer B
    Cardiol J; 2019; 26(6):711-716. PubMed ID: 30484267
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk factors and the effect of cardiac resynchronization therapy on cardiac and non-cardiac mortality in MADIT-CRT.
    Perkiomaki JS; Ruwald AC; Kutyifa V; Ruwald MH; Mcnitt S; Polonsky B; Goldstein RE; Haigney MC; Krone RJ; Zareba W; Moss AJ;
    Europace; 2015 Dec; 17(12):1816-22. PubMed ID: 26071234
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SCD-HeFT: Use of R-R interval statistics for long-term risk stratification for arrhythmic sudden cardiac death.
    Au-Yeung WT; Reinhall PG; Poole JE; Anderson J; Johnson G; Fletcher RD; Moore HJ; Mark DB; Lee KL; Bardy GH
    Heart Rhythm; 2015 Oct; 12(10):2058-66. PubMed ID: 26096609
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Developing a risk score to predict mortality in the first year after implantable cardioverter defibrillator implantation: Data from the Israeli ICD Registry.
    Nevzorov R; Goldenberg I; Konstantino Y; Golovchiner G; Strasberg B; Souleiman M; Khalameizer V; Ben-Zvi S; Sela R; Rosenheck S; Freedberg NA; Geist M; Cohen ME; Cohen T; Shlomo N; Gabrielov-Yusim N; Geva D; Glikson M; Haim M;
    J Cardiovasc Electrophysiol; 2018 Nov; 29(11):1540-1547. PubMed ID: 30168227
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Importance of Implantable Cardioverter-Defibrillator Back-Up in Cardiac Resynchronization Therapy Recipients: A Systematic Review and Meta-Analysis.
    Barra S; Providência R; Tang A; Heck P; Virdee M; Agarwal S
    J Am Heart Assoc; 2015 Nov; 4(11):. PubMed ID: 26546574
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prophylactic Use of Implantable Cardioverter-Defibrillators in the Prevention of Sudden Cardiac Death in Dialysis Patients.
    Jukema JW; Timal RJ; Rotmans JI; Hensen LCR; Buiten MS; de Bie MK; Putter H; Zwinderman AH; van Erven L; Krol-van Straaten MJ; Hommes N; Gabreëls B; van Dorp W; van Dam B; Herzog CA; Schalij MJ; Rabelink TJ;
    Circulation; 2019 Jun; 139(23):2628-2638. PubMed ID: 30882234
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Seattle Heart Failure and Proportional Risk Models Predict Benefit From Implantable Cardioverter-Defibrillators.
    Bilchick KC; Wang Y; Cheng A; Curtis JP; Dharmarajan K; Stukenborg GJ; Shadman R; Anand I; Lund LH; Dahlström U; Sartipy U; Maggioni A; Swedberg K; O'Conner C; Levy WC
    J Am Coll Cardiol; 2017 May; 69(21):2606-2618. PubMed ID: 28545633
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.